Clinical effect of Somalutide on patients with type 2 diabetes mellitus
WANG Mengying1 ZHANG Hecheng1 WANG Fang1 YE Qibao2
1.Department of Endocrinology, Suzhou Hospital Affiliated to Anhui Medical University, Anhui Province, Suzhou 234000, China;
2.Department of Endocrinology, Binhu District, Hefei First People’s Hospital, Anhui Province, Hefei 233000, China
Abstract：Objective To explore the clinical effect of Somalutide on patients with type 2 diabetes mellitus (T2DM). Methods A total of 160 patients with T2DM admitted to Suzhou Hospital Affiliated to Anhui Medical University from January 2019 to December 2021 were selected, and they were divided into observation group and control group by random number table method, with 80 cases in each group. The control group was treated with Metformin orally, the observation group was treated with Somarlutide based on the control group. The treatment cycle of the two groups was three months. Body mass index (BMI), blood glucose indexes (fasting blood glucose [FBG], 2-hour postprandial blood glucose [2hPBG], glycosylated hemoglobin [HbAlc]), blood lipid indexes (total cholesterol [TC], triglyceride [TG], low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C]), and serum inflammatory index (the levels of hypersensitive C-reactive protein [hs-CRP], tumor necrosis factor-α [TNF-α], interleukin-6 [IL-6] ) were compared between the two groups before and after treatment, and the incidence of adverse reactions were compared between the two groups. The incidence of adverse reactions was compared between the two groups. Results After treatment, BMI and blood glucose levels in the two groups were lower than before treatment, and the observation group was lower than the control group, the differences were statistically significant (P＜0.05). After treatment, TG, TC and LDL-C in two groups were lower than before treatment, and HDL-C was higher than before treatment. TG, TC and LDL-C in observation group were lower than control group, and HDL-C was higher than control group, the differences were statistically significant (P＜0.05). After treatment, the levels of inflammatory factors in the two groups were lower than before treatment and the observation group was lower than the control group, the differences were statistically significant (P＜0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion Somaluptide is more effective in the treatment of T2DM. It can effectively improve blood glucose, blood lipid and inflammatory indicators, reduce the weight of patients without obvious adverse reactions. It is recommended for clinical application.
王梦莹1 张贺成1 王芳1 叶启宝2. 索马鲁肽治疗2型糖尿病患者的临床效果[J]. 中国医药导报, 2023, 20(12): 86-89.
WANG Mengying1 ZHANG Hecheng1 WANG Fang1 YE Qibao2. Clinical effect of Somalutide on patients with type 2 diabetes mellitus. 中国医药导报, 2023, 20(12): 86-89.
[1] Laouali N，Shah S，Macdonald CJ，et al. BMI in the Associations of Plant-Based Diets with Type 2 Diabetes and Hypertension Risks in Women：The E3N Prospective Cohort Study [J]. J Nut，2021，151（9）：2731-2740..
[2] 孙晓方，阎胜利，王越，等.利拉鲁肽对肥胖2型糖尿病患者胰高血糖素分泌功能的影响[J].中华内科杂志，2019， 58（1）：33-38.
[3] 夏阳阳，顾天伟，蒋春明，等.2型糖尿病患者发生慢性肾脏病的危险因素及与肥胖的相关性研究[J].中华糖尿病杂志，2022，14（2）：140-146.
[4] 吴世卫，陈瑜，马晓军，等.二甲双胍调控糖尿病大鼠骨髓间充质干细胞的增殖和分化[J].基因组学与应用生物学，2020，39（2）：909-913.
[5] 芦志伟，孙浩，李莹，等.长效GLP-1受体激动药索马鲁肽治疗2型糖尿病疗效和安全性的系统评价[J].中国药房，2019，30（7）：969-975.
[6] 中华医学会糖尿病学分会.中国2型糖尿病防治指南（2017年版）[J].中华糖尿病杂志，2018，10（1）：4-67.
[7] 刘金刚，郑成竹，王勇.中国肥胖和2型糖尿病外科治疗指南（2014）[J].中国实用外科杂志，2014，34（11）：1005-1110.
[8] 徐礼五，钟兴，齐晓玲，等.新诊断超重/肥胖2型糖尿病在短期胰岛素强化治疗后转换不同降糖方案的临床疗效和安全性研究[J].安徽医科大学学报，2019，54（2）：303-306.
[9] 郭立新.2021年糖尿病领域年度重大进展回顾[J].中华糖尿病杂志，2022，14（1）：1-8.
[10] 张咪，梁伟，许祥.达格列净和西格列汀治疗超重及肥胖2型糖尿病的疗效及安全性对比[J].实用医学杂志，2021，37（9）：1182-1186.
[11] 李鲁波，翁军玲，李健辉.利拉鲁肽联合二甲双胍对肥胖2型糖尿病患者的临床疗效及血清趋化素，内脂素水平的影响[J].重庆医学，2019，48（S02）：72-74.
[12] 彭湾湾，薛君力.恩格列净联合胰岛素强化治疗肥胖2型糖尿病患者的疗效与安全性[J].实用医学杂志，2019， 35（20）：3223-3226.
[13] Gormsrn LC，S?覬ndergaard E，Christensen NL，et al. Metformin increases endogenous glucose production in non-diabetic individuals and individuals with recent-onset type 2 diabetes [J]. Diabetologia，2019，62（7）：1251-1256.
[14] 张文竹，孙韬华，石杰.首个口服胰高血糖素样肽-1受体激动剂索马鲁肽[J].中国新药杂志，2020，29（22）：2552- 2556.
[15] 李梦雅，钟小燕，刘鑫，等.口服索马鲁肽治疗2型糖尿病有效性和安全性的Meta分析[J].中国新药与临床杂志，2020，39（6）：367-373.
[16] 王姗姗，李琳，郑睿智，等.热量限制对2型糖尿病患者糖代谢影响的研究现状[J].中华内分泌代谢杂志，2019， 35（3）：254-258.
[17] 秦元，周俊凝，张春燕，等.索马鲁肽治疗2型糖尿病疗效与安全性的系统评价[J].沈阳药科大学学报，2019， 36（7）：636-641.
[18] Mann J，Muskiet M. Incretin-based drugs and the kidney in type 2 diabetes： choosing between DPP-4 inhibitors and GLP-1 receptor agonists-ScienceDirect [J]. Kidney International，2021，99（ 2）：314-318.
[19] Osinski C，Gléau LL，Poitou C，et al. Type 2 diabetes is associated with impaired jejunal enteroendocrine GLP-1 cell lineage in human obesity [J]. International J Obes （Lond），2021，45（1）：170-183.
[20] Dahik VD，Frisdal E，Goff WL. Rewiring of Lipid Metabolism in Adipose Tissue Macrophages in Obesity： Impact on Insulin Resistance and Type 2 Diabetes [J]. Int J Mol Sci，2020，21（15）：5505-5535.
[21] 陈源，李振华，岳仁宋，等.黄连-大黄调控NLRP3炎性小体对2型糖尿病大鼠肝脏胰岛素抵抗的影响[J].北京中医药大学学报，2022，45（7）：699-708.
[22] Jta B，Sa C，Akm A，et al. Vitamin A levels are decreased but not influenced by glucose or lipid-lowering medications in subjects with type 2 diabetes-ScienceDirect [J]. Saudi J Biol Sci，2021，28（1）：572-577.
[23] Newsome P，Francque S，Harrison S，et al. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity [J]. Aliment Pharmacol Ther，2019，50（2）：193-203.
[24] Alzamil H. Elevated Serum TNF-α Is Related to Obesity in Type 2 Diabetes Mellitus and Is Associated with Glycemic Control and Insulin Resistance [J]. J Obes，2020，2020（3）：1-5.
[25] 林媛媛，黄雪梅，邹欣婷，等.正性共刺激分子ICOS/ICOSL，OX40/OX40L对老年2型糖尿病免疫炎症的调节作用[J].中国老年学杂志，2020，40（11）：2280-2283.
[26] 方雅萱，钟柯，倪清颖，等.糖尿病肾病炎症生物标志物的研究进展[J].中国医药导报，2021，18（35）：38-41.
[27] 郭世强，刘春林，吴清念.糖尿病肾病患者肠道菌群及炎症因子变化的临床意义[J].中国当代医药，2022，29（21）：23-26.
京公网安备 11010502046598号